#

Pharmaceutical Companies

: 119
The companys experimental shot reduced the frequency and severity of hot flashes over a four-week study compared with a placebo, with no serious side effects / Photo: AbCellera
Small Caps·
Mid-cap hot-flash drugmaker AbCellera soars on upbeat mid-stage clinical data
Sionna will now shelve its cystic fibrosis drug candidate / Photo: LinkedIn/Sionna Therapeutics
Small Caps·
Sionna's cystic fibrosis drug candidate fails in trial; stock craters 90%
The company listed on NASDAQ under the ticker symbol BLSM. Photo: BlossomHill
News·
BlossomHill Therapeutics IPO: Cancer Drug Developer Goes Public
Photo: Seacalm/Shutterstock
News·
Braveheart Bio IPO: Shares in the cardiovascular drug developer are now available
Eli Lilly Raises Forecast Thanks to the Success of Its Weight-Loss Drugs / Photo: Tada Image / Shutterstock.com
News·
Lilly raised its revenue forecast. This eased fears that the weight-loss boom is on the decline
Novo Nordisk shares fell after the company reported disappointing sales results for its weight-loss drug / Photo: Shutterstock.com / Kittyfly
News·
Weak sales of Wegovy overshadowed Novo's "clearly less-than-impressive" forecast revision
Shares of AstraZeneca, a British biopharmaceutical giant, fell nearly 7%. Photo: Mats Wiklund/Shutterstock
News·
AstraZeneca shares plummeted following news of a mega-deal with Bristol Myers
The failure of Novo Nordisks drug trials sent its stock tumbling 10% / Photo: JHVEPhoto / Shutterstock
News·
Novo Nordisk shares plummeted 10% after a heart drug trial failed
Novo Nordisk shareholders have succeeded in securing the launch of a judicial investigation into the results of testing for the drug CagriSema / Photo: gguy / Shutterstock
News·
Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug
Hedge funds have increased their exposure to healthcare stocks to a nearly five-year high
News·
Hedge funds have increased their exposure to healthcare stocks to a nearly five-year high
Profits at British pharmaceutical giant AstraZeneca exceeded analysts expectations last quarter. Photo: Konektus Photo/Shutterstock
News·
Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?
Pharmaceutical giant Eli Lilly is a shareholder of Scribe / Photo: sasirin pamai / Shutterstock
News·
IPO Scribe: Shares in a biotech company backed by Eli Lilly and Sanofi are now available
Load more